CYP2C19 Rapid Genotyping

We turnaround the CYP2C19 result within 24-72h, in order to deliver the maximum clinical value to the patients.

CYP2C19 Rapid Genotyping

We turnaround the CYP2C19 result within 24-72h, in order to deliver the maximum clinical value to the patients.

Actionable PGx panel for diverse populations

RPRD proudly launches a highly clinically actionable "PGx 25 Gene Panel", specially curated for multi-ethnicities.

Actionable PGx panel for diverse populations

RPRD proudly launches a highly clinically actionable "PGx 25 Gene Panel", specially curated for multi-ethnicities.

Sample home collection

RPRD offer sample collection from the comfort and privacy of the patient's own home, with no extra cost.

Sample home collection

RPRD offer sample collection from the comfort and privacy of the patient's own home, with no extra cost.
DNA strand for Precision Medicine

Pharamcogenomics for diverse populations

Why the ethnicity-inclusive PGx testing?

Pharamcogenomics for diverse populations

Why the ethnicity-inclusive PGx testing?

How Personalized Medicine Improves Patient Care

Not every drug works for every patient. The traditional trial-and-error method to prescribe therapy, at times, lead to adverse drug reactions (ADRs) and reduced drug efficacy. Thanks to the rapidly developing genomic medicine technologies, we have uncovered the associations between individual’s genetic profiles and response to certain drugs. This scientific breakthrough is called Pharmacogenomics, or PGx.

RPRD was founded in 2017 by scientists and clinicians from the Medical College of Wisconsin to use the PGx knowledge to personalize therapy, boosting drug safety and efficacy.

 

Why Partner with RPRD?

The most comprehensive PGx testing

RPRD’s flagship PGx testing, Whole Pharmacogenomics Scan (WPS®) is the most comprehensive, customizable, and scalable preemptive PGx test, which can analyze nearly all actionable pharmacogenetic genes of a patient with a single, one-time test.

 

PGx testing for diverse populations

RPRD’s PGx testing not only investigate the common genetic alleles, but also the rare and the ethnicity-specific variants, to generate inclusive and ethnicity-unbiased highly accurate testing results that every provider and patient can trust.

Leader in genomics research and clinical PGx testing

EMPOWER PERSONALIZED CARE

End-to-end solutions to enable precision medicine

We leverage advanced technologies and our decades-long experience in genetics research to bring pharmacogenetics into the mainstream. We empower clinicians with complete solutions, so they can focus on providing better care for their patients.

Evidence-based high-quality solutions

Our PGx solutions are formulated based on the latest clinical practice guidelines, which are supported by rigorous peer-reviewed clinical and scientific evidence.

Genetics in Drug Responses

ACCELERATE PERSONALIZED THERAPIES

Our drug development partners trust our academic excellence and decades of scientific research experience in genetics and the impact of genetics on drug responses. Through our continued research in modern technologies and drug R&D, we help our partners pursue personalized therapies to achieve better care for tomorrow.

Border Image
Latest Insights
Webinar Recording: Impact of CYP2D6 PGx

CYP2D6 is an important pharmacogenetics (PGx) gene as it is involved in the metablism of ~25% of clinically prescribed drugs. Dr. Cyrine-Eliana Haidar at St Jude Children’s Research Hospital will discuss how to use CYP2D6 genetic information to guide drug dosing and improve patient care, with focus on her many years of experience in managing the medications that are important in oncology care, including ondansetron, tamoxifen, select antidepressant and pain medicines.

Webinar Recording: PGx for Minorities

Health disparities exist among various ethnicity groups in the United States, with differences observed in disease prevalence, mortality, and medication responses. Together with multiple social-economic factors, genetic variations contribute to the variability across the populations. Despite the tremendous progress made in PGx research in the past decades, most of the studies have been conducted mainly on population of European descent. Recently, considerable attention has focused on advancing our understanding of how PGx can be used to address health disparities. The presentation will review current approaches for PGx testing, different approaches to and infrastructure needs for implementation.

Podcast: the Voice of Healthcare

Dr. Hyun Kim, Clinical Pharmacist with Boston Children’s Clinical Pharmacogenomics Service and Dr. Ulrich (Uli) Broeckel, Founder and CEO of RPRD explore pharmacogenetics and precision medicine, the application to clinical medicine and decision making, and most importantly, the benefits to patients and clinical teams.

Understanding the relationship between an individual’s genetic profile and their pharmacokinetics is very important to our clinical studies. RPRD’s breadth of experience with comprehensive PGx-profiling tests and in-depth data analysis is exactly what we were looking for. I would highly recommend their services. 

- Simon Wong, Director, DMPK, Pliant Therapeutics

Unlock the power of science

RPRD is accelerating personalized therapies of tomorrow through its long-term commitment to advancing PGx with scientific breakthroughs and innovations.

PGx Diagnostic Solutions

RPRD’s experience in precision medicine and its CLIA-certified laboratory offer a wide range of PGx diagnostic services to meet your unique needs.

References
  1. Spear BB, et al. Clinical Application of Pharmacogenetics. Trends Mol. Med. 2001 May;7(5):201-4.
  2. FDA “Preventable Adverse Drug Reactions.” 2018.
  3. Relling MV, et al. Pharmacogenomics in the Clinic. Nature. 2015 Oct;526(7573):343-50.
  4. Ji Y, et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol. Diagn. 2016 May;18(3):438-46.
  5. Dunnenberger HM, et al. Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annu Rev Pharmacol Toxicol. 2015 Jan;55:89-106.